Skip to main content
. 2023 Aug 3;149(9):847–849. doi: 10.1001/jamaoto.2023.1729

Figure 2. Survival According to Pathologic Response.

Figure 2.

Kaplan-Meier estimates of disease-free survival (DFS) (A), disease-specific survival (DSS) (B), and overall survival (OS) (C) among 20 patients with stage III/IV cutaneous squamous cell carcinoma (CSCC) of the head and neck who were treated with 2 doses of neoadjuvant cemiplimab. Pathologic responders (pathologic complete response [pCR] or major pathologic response [MPR]) demonstrated improved DFS (hazard ratio [HR], 0.092; 95% CI, 0.010-0.886) but not DSS (HR, 0; 95%CI, 0 to infinity, convergence) or OS (HR, 0.298; 95% CI, 0.019-4.787) compared with nonresponders.